Stockscreener 앱 받기
2.70
10.89%
-0.33
시간 외 거래:
2.75
0.05
+1.85%
전일 마감가:
$3.03
열려 있는:
$3
하루 거래량:
3.10M
Relative Volume:
3.15
시가총액:
$133.36M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-1.5607
EPS:
-1.73
순현금흐름:
$-54.24M
1주 성능:
-39.46%
1개월 성능:
-44.95%
6개월 성능:
-78.14%
1년 성능:
-84.97%
1일 변동 폭
$2.61
$3.0954
1주일 범위
$2.61
$4.49
52주 변동 폭
$2.61
$26.35
Cabaletta Bio Inc Stock (CABA) Company Profile
명칭
Cabaletta Bio Inc
전화
(267) 759-3100
주소
2929 ARCH STREET, PHILADELPHIA, PA
CABA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CABA | 2.70 | 133.36M | 0 | -67.68M | -54.24M | -1.73 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-07-18 | 개시 | Guggenheim | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-01-08 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-13 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 개시 | Cowen | Outperform |
| 2019-11-19 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MyChesCo
Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat
Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK
Cabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC Wainwright - MarketBeat
T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK
Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartzy
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times
Vanguard Group Inc's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
UBS Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation - MSN
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in October - MarketBeat
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Hol - GuruFocus.com
Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Drops By 16.7% - MarketBeat
Trading Day Review: Cabaletta Bio Inc (CABA) Gains Momentum, Closing at 4.21 - The Dwinnex
Millennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
UBS sees significant upside for Cabaletta Bio despite recent share decline - Investing.com India
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Healthy Upside Potential: Cabaletta Bio Inc (CABA) - SETE News
UBS sees significant upside for Cabaletta Bio despite recent share decline By Investing.com - Investing.com South Africa
Cabaletta Bio (NASDAQ:CABA) Now Covered by Analysts at UBS Group - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
A Guide To The Risks Of Investing In Cabaletta Bio Inc (CABA) - Knox Daily
Cabaletta Bio Inc (CABA) stock analysis: A comprehensive overview - US Post News
Cabaletta Bio Outlines Future Trials and Development Strategy - TipRanks
Squarepoint Ops LLC Has $2.36 Million Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Marshall Wace LLP Grows Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Get in on Cabaletta Bio Inc’s (CABA) buy-in window today! - SETE News
Should investors be concerned about Cabaletta Bio Inc (CABA)? - US Post News
Cabaletta Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Cabaletta Bio secures lease terms through August 2026 - Investing.com India
Cabaletta Bio secures lease terms through August 2026 By Investing.com - Investing.com South Africa
Ratios Reveal: Breaking Down Cabaletta Bio Inc (CABA)’s Financial Health - The Dwinnex
Perceptive Advisors LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Lynx1 Capital Management LP Lowers Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Wall Street SWOT: Cabaletta Bio stock pioneers CAR-T in immunology amid challenges - Investing.com
Lynx1 Capital Management LP Has $3.68 Million Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 - ForexTV.com
Cabaletta Bio Inc (CABA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):